Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

491
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
491
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

522
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
522
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

26.7K
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
26.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to Lipid-Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.

Journal of the American Heart Association·2025
Same author

Impact of Lipid and ASCVD-Modulating Agents on Glycemia and New-Onset Diabetes or Prediabetes.

JACC. Advances·2025
Same author

Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl.

Frontiers in cardiovascular medicine·2025
Same author

Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data.

Journal of clinical lipidology·2025
Same author

Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.

Current opinion in lipidology·2023
Same author

Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol.

American journal of preventive cardiology·2021

Related Experiment Video

Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

When to lower triglycerides?

Om P Ganda1

  • 1Clinical Research and Adult Diabetes sections, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Current Opinion in Lipidology
|June 11, 2020
PubMed
Summary

High triglyceride-rich particles (TRL) increase cardiovascular risk. Icosapent-ethyl (IPE), an omega-3 fatty acid, significantly reduced ASCVD events in high-risk patients, suggesting novel therapeutic benefits beyond triglyceride lowering.

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Residual risk of atherosclerotic cardiovascular disease (ASCVD) events persists despite statin therapy.
  • Triglyceride-rich particles (TRL) and associated dyslipidemia factors contribute to atherogenesis.
  • Increasing prevalence of high triglycerides linked to lifestyle, obesity, and diabetes.

Purpose of the Study:

  • To review the role of TRL in ASCVD.
  • To evaluate therapeutic strategies for residual dyslipidemia.
  • To assess the impact of icosapent-ethyl (IPE) on ASCVD events.

Main Methods:

  • Review of clinical trial data on fibrates, niacin, and omega-3 fatty acids (OM3FA).
  • Analysis of evidence linking TRL to atherogenesis.

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
The TreadWheel: Interval Training Protocol for Gently Induced Exercise in Drosophila melanogaster
07:21

The TreadWheel: Interval Training Protocol for Gently Induced Exercise in Drosophila melanogaster

Published on: June 8, 2018

12.1K

Related Experiment Videos

Last Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
The TreadWheel: Interval Training Protocol for Gently Induced Exercise in Drosophila melanogaster
07:21

The TreadWheel: Interval Training Protocol for Gently Induced Exercise in Drosophila melanogaster

Published on: June 8, 2018

12.1K
  • Evaluation of IPE's effect on ASCVD events in high-risk populations.

    • Main Results:

    • Past trials with fibrates and niacin showed no ASCVD benefit post-statin.
    • Icosapent-ethyl (IPE) demonstrated a 25% ASCVD event reduction in high-risk patients.
    • IPE's benefits may stem from unique biological effects beyond triglyceride reduction.

    Conclusions:

    • IPE shows promise in preventing ASCVD events in high-risk individuals.
    • Novel agents like Apo C-III inhibitors may benefit patients with very high triglycerides.
    • Further research into TRL management and novel therapies is warranted.